If successful, the company aims to initially offer the drug to patients previously enrolled in clinical studies of the drug. The new drug is called aducanumab. It targets a protein called amyloid that forms abnormal deposits the brains of people with Alzheimer’s. There haven’t been any new dementia drugs in over a decade. Aducanumab reduced clinical decline in patients with early Alzheimer’s disease on multiple measures of the drug’s effectiveness.
“We are hopeful about the prospect of offering patients the first therapy to reduce the clinical decline of Alzheimer’s disease and the potential implication of these results for similar approaches targeting amyloid beta,” Michel Vounatsos, Biogen’s chief executive, said in a statement. “People affected by Alzheimer’s have waited a long time for a life-changing new treatment and this exciting announcement offers new hope that one could be in sight,” Hilary Evans from Alzheimer’s Research UK said. „We currently have no effective treatments to slow or halt the progression of Alzheimer’s disease and I hope this signifies a turning point,” Prof Bart De Strooper, Director of the UK Dementia Research Institute at University College London declared.